
LSP leads €21m round into Neurent Medical
Galway-based medical device company Neurent Medical, which is focussed on chronic inflammatory diseases of the sinuses and nasal passages said it...

Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

Cell and gene therapy specialist Minaris expanding
In Europe, the Showa Denko Materials Co., Ltd. subsidiary will invest US$40.7 million to build a new state-of-the-art facility in proximity to an...

Galecto raise US$85m in Nasdaq IPO
The IPO money infusion for the Danish company came just two weeks after Galecto AB had closed a US$64m Series D round, with a share price of...

COVID-19: Moderna reports promising interim results
On Monday, Moderna Inc. announced that two 100µg shots of its mRNA COVID-19 vaccine candidate mRNA-1273 showed an efficacy of 94,5%, according to an...

Polyphor AG bags funding for murepavadin
Swiss Polyphor AG (Allschwil) is developing its lead Outer Membrane Protein Targeting Antibiotic (OMPTA) candidate inhaled murepavadin against...

Bioinvent AB licences BI-1206 to CASI Pharmaceuticals
Cancer antibody specialist BioInvent International AB has granted the exclusive rights to market its anti-FcγRIIB antibody, BI-1206, in China,...